5 Must-Read Analyst Questions From Aflac’s Q1 Earnings Call

Aflac’s first quarter results fell short of Wall Street’s expectations, with both revenue and adjusted earnings per share missing consensus estimates. The market responded negatively, with shares declining after the announcement. Management highlighted strong sales momentum in Japan, particularly from new medical and cancer insurance products, but acknowledged ongoing challenges in maintaining earned premium growth. CEO Daniel Amos pointed to the company’s focus on persistency and distribution channel expansion as key operational themes, while CFO Max Broden discussed pressures from lapses and the impact of reinsurance transactions on near-term earnings.

Is now the time to buy AFL? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Aflac’s Q1 Earnings Call

• Tom Gallagher (Evercore ISI) asked about the benefit of the new reinsurance deal and ESR headwinds in Japan. CFO Max Broden said the transaction’s impact was relatively small and explained that the main driver of ESR changes was subsidiary dividends and yen-rate sensitivity.
• Ryan Krueger (KBW) questioned the drivers of improvement in Japan’s benefit ratio. Broden detailed that underlying experience, net premium ratio, and lapse mix would shape ratios, reiterating confidence in the 60%-63% outlook for the year.
• Suneet Kamath (Jefferies) challenged whether the reinsurance strategy indicated less core business growth in Japan. CEO Daniel Amos replied that Aflac still sees opportunity in Japan and views reinsurance as a natural, evolutionary expansion, not a replacement for organic growth.
• Francis Matten (BMO Capital Markets) asked what would be needed for Japan’s earned premium growth to inflect positive. Broden responded that sales must reach about JPY 90 billion annually; current sales are below that threshold, but management is targeting higher volumes.
• Wilma Jackson Burdis (Raymond James) inquired about plans for deploying excess capital and the potential for larger reinsurance deals. Broden confirmed that while reinsurance will consume some capital, it will not alter shareholder capital deployment priorities and should diversify earnings.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will closely monitor (1) whether new product launches in Japan continue to drive sales momentum and begin to improve underlying earned premium growth, (2) progress in revitalizing the U.S. agent channel and sustaining group business gains, and (3) the scale and profitability of further reinsurance transactions in Japan. Additionally, we will track how persistency trends and cost controls impact margins across segments.

Aflac currently trades at $114.53, down from $116.21 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.